At the time of writing, Keros Therapeutics Inc [KROS] stock is trading at $52.93, up 10.76%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KROS shares have gain 16.66% over the last week, with a monthly amount glided 12.12%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Keros Therapeutics Inc [NASDAQ: KROS] stock has seen the most recent analyst activity on June 25, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $102. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $60 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $86 on July 31, 2023. BofA Securities initiated its recommendation with a Buy and recommended $65 as its price target on July 26, 2023. In a note dated October 18, 2022, Truist initiated an Buy rating and provided a target price of $100 on this stock.
For the past year, the stock price of Keros Therapeutics Inc fluctuated between $27.02 and $73.00. Currently, Wall Street analysts expect the stock to reach $105 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $52.93 at the most recent close of the market. An investor can expect a potential return of 98.38% based on the average KROS price forecast.
Analyzing the KROS fundamentals
Gross Profit Margin for this corporation currently stands at -4.1% with Operating Profit Margin at -696.15%, Pretax Profit Margin comes in at -620.13%, and Net Profit Margin reading is -620.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.45 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 48.88 points at the first support level, and at 44.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 55.80, and for the 2nd resistance point, it is at 58.67.
Ratios To Look Out For
It is important to note that Keros Therapeutics Inc [NASDAQ:KROS] has a current ratio of 20.37. Also, the Quick Ratio is 20.37, while the Cash Ratio stands at 19.1. Considering the valuation of this stock, the price to sales ratio is 7355.31, the price to book ratio is 4.55.
Transactions by insiders
Recent insider trading involved GORDON CARL L, Director, that happened on Aug 13 ’24 when 0.25 million shares were sold. Director, ORBIMED ADVISORS LLC completed a deal on Aug 13 ’24 to sell 0.25 million shares. Meanwhile, Shareholder OrbiMed Genesis Master Fund, L bought 29400.0 shares on Aug 13 ’24.
